Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
AssigneesInstitut Curie, INSERM(Institut National de la Sante et de la Rcherche Medicale)
InventorsMarc-Henri Stern, Elodie Manie, Tatiana Popova
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.
Claims9
A method for treating cancer, the method comprising a therapeutically effective amount of a PARP inhibitor and/or an alkylating agent to a human patient identified as having, in a tumor sample obtained from the patient, a number, per genome, of large scale transitions (LSTs) greater than a predetermined threshold number of LSTs, wherein an LST is a breakpoint between two genomic regions of different copy number, each such genomic region greater than or equal to 3 and less than 6 megabases long.
Dependencies are inferred from the claim text.